Scarica l'app Stockscreener
108.62
1.50%
1.60
Dopo l'orario di chiusura:
108.66
0.04
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192 - GuruFocus
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
BMO Capital Initiates Insmed at Outperform With $192 Price Target - marketscreener.com
Is Insmed (INSM) Priced Too Richly For Its Phase 3 Progress? - Yahoo Finance
Insmed (INSM) Following TPIP 12 Month Data, Does The Valuation Still Stack Up - Yahoo Finance
BMO initiates Insmed stock with outperform rating on respiratory franchise potential - Investing.com Nigeria
Insmed Announces Positive 12-Month Data from OLE Study of Inhalation Solution for Pulmonary Arterial Hypertension - dicardiology.com
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Positive 12‑Month TPIP PAH Data Could Be A Game Changer For Insmed (INSM) - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Buy Insmed for a double, this analyst says - Cantech Letter
Investors’ Concerns Hurt Insmed Incorporated (INSM) Despite Better-Than-Expected Results - Yahoo Finance
Insmed stock price target maintained at $220 by H.C. Wainwright - Investing.com Canada
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3 - webull.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237 - Moomoo
Open-label extension drives home benefits of Insmed’s PAH therapy - BioWorld News
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $207 - Moomoo
Insmed stock price target maintained at $200 by Stifel on trial data - Investing.com Canada
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning - Benzinga
INSM: TPIP sustained robust efficacy and safety at 12 months, with 65% reaching refined low-risk status - TradingView
Insmed (INSM) Reports Promising 12-Month Results for TPIP in PAH Patients - GuruFocus
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study - Yahoo Finance
INSM: TPIP sustained best-in-class efficacy and safety at 12 months, with 65% reaching low-risk status - TradingView
Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients - Moomoo
Insmed reports 12-month data for PAH treatment candidate By Investing.com - Investing.com Canada
Insmed reports 12-month data for PAH treatment candidate - Investing.com
Insmed reports positive 12-month OLE results for TPIP showing sustained 6MWD, ~60% NT-proBNP drop - TradingView
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension - PR Newswire
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
INSM Maintained by Wells Fargo -- Price Target Raised to $161 - GuruFocus
William Haggerty Joins Insmed Incorporated as Senior Director of People Operations - hrtoday.in
Enterprise value to EBIT forward of Insmed Incorporated – BMV:INSM - TradingView
MSN Money - MSN
What's Driving Insmed's Recent Volatility - Kavout | AI
Enterprise value to revenue forward of Insmed Incorporated – BMV:INSM - TradingView
Insmed CEO William Lewis sells over $1.25m in company stock - Investing.com Australia
Insmed CEO William Lewis sells over $1.25m in company stock By Investing.com - Investing.com India
Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing - Moomoo
Form 4 Insmed Inc For: 10 July By Investing.com - Investing.com South Africa
INSMED Inc (NASDAQ: INSM) CEO executes 10b5-1 option exercise and sale of 10,699 shares - Stock Titan
INSM Reiterated by Guggenheim -- Price Target Maintained at $207 - GuruFocus
Insmed Slides 4% as Investors Weigh Insider Filing and Near-Term Catalyst Gap - Moomoo
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $207 - Moomoo
Form 144 INSMED INC For: 9 July By Investing.com - Investing.com India
INSM (NASDAQ: INSM) affiliate William Lewis reports multiple share sales - Stock Titan
INSM Technical Analysis & Stock Price Forecast - Intellectia AI
Insmed CMO Martina Flammer sells $1.35m in stock - Investing.com
0.29%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):